Search our Database of Scientific Publications and Authors

I’m looking for a

    Details and Download Full Text PDF:
    Angioedema Two Weeks After the Initial Administration of an ACE Inhibitor.

    Dtsch Arztebl Int 2018 Mar;115(9):142
    PDF Download - Full Text Link
    ( Please be advised that this article is hosted on an external website not affiliated with
    Source Status ListingPossible

    Similar Publications

    Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema.
    J Allergy Clin Immunol 2017 Jul 29;140(1):242-248.e2. Epub 2016 Nov 29.
    Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn. Electronic address:
    Background: The B receptor antagonist icatibant is approved for treatment of attacks of hereditary angioedema. Icatibant has been reported to decrease time-to-resolution of angiotensin-converting enzyme (ACE) inhibitor-associated angioedema in 1 study of European patients.

    Objective: We sought to test the hypothesis that a bradykinin B receptor antagonist would shorten time-to-resolution from ACE inhibitor-associated angioedema. Read More
    Current concepts of pharmacotherapy in hypertension: ACE inhibitor-related angioedema: can angiotensin-receptor blockers be safely used?
    J Clin Hypertens (Greenwich) 2002 Sep-Oct;4(5):375-80
    Department of Medicine, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA.
    Angioedema is a well-recognized side effect of angiotensin-converting enzyme (ACE) inhibitor therapy. Angioedema can also be seen with angiotensin receptor blocker therapy but much less frequently than is the case with ACE inhibitors. For unclear reasons, ACE inhibitor-related angioedema occurs more commonly in black patients. Read More
    Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment.
    Arch Intern Med 2004 Apr;164(8):910-3
    Department of Internal Medicine, University of Milan, IRCCS Ospedale Maggiore, Via Pace 9, 20122 Milan, Italy.
    Background: Angiotensin-converting enzyme (ACE) inhibitors are associated with angioedema episodes that are potentially life-threatening. Few data are available on the outcome of patients reporting this adverse effect when they are switched to another drug. Scattered reports of angioedema associated with angiotensin II receptor blocker (ARB) use question the safety of using these drugs in patients with ACE inhibitor-related angioedema. Read More
    Association of angiotensin-converting enzyme inhibitor-associated angioedema with transplant and immunosuppressant use.
    Allergy 2010 Nov;65(11):1381-7
    Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.
    Background: Immunosuppressants decrease circulating dipeptidyl peptidase IV (DPPIV) activity in transplant patients, and decreased DPPIV activity has been associated with angiotensin-converting enzyme (ACE) inhibitor-associated angioedema. One study has reported an increased incidence of ACE inhibitor-associated angioedema among transplant patients compared to published rates, while several case series report angioedema in patients taking specific immunosuppressant agents.

    Objective: To test the hypothesis that transplant patients are at increased risk of ACE inhibitor-associated angioedema. Read More